Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma

Barrington, Sally F.; Qian, Wendi; Somer, Edward J.; Franceschetto, Antonella; Bagni, B; Brun, Eva; Almquist, Helén; Loft, Annika; Højgaard, Liselotte; Federico, Massimo; Gallamini, Andrea; Smith, Paul J.; Johnson, Peter; Radford, John; O’Doherty, Michael

doi:10.1007/s00259-010-1490-5

Cited by 295 publications

(215 citation statements)

References 24 publications

Supporting

Mentioning

196

Contrasting

Unclassified

Order By: Relevance

“…A concern using a five-point scale may be the introduction of greater variability in interpretation amongst readers. However, as previously shown for HL and diffuse large B-cell lymphoma and as also supported by our data, the clinical significance of minor disagreements amongst readers may not be high and agreement in defining positive and negative scans is excellent [25,30].…”

Section: Discussionsupporting

confidence: 89%

FDG PET/CT Response Assessment Criteria for Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma at End of Therapy: A Multiparametric Approach

Metser

Mohan

Beckley

et al. 2015

Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose Based on the International Harmonization Project (IHP) criteria, positron emission tomography (PET) response assessment of residual nodal masses in patients with lymphoma after completion of therapy is performed visually using mediastinal blood pool as the reference. The primary objective of this study was to define the optimal reference for PET response assessment. Secondary aim was to assess if morphological criteria on computed tomography (CT) may improve performance of PET. Methods This institutional review board approved retrospective study included 137 patients, with Hodgkin's (n=43) or non-Hodgkin's lymphoma (n = 94) assessed for residual masses (n=180) after completion of therapy with pathology and clinical and imaging surveillance data (mean, 19 months) as the standard of reference. Two readers independently assessed response by IHP and Deauville criteria. The addition of morphological parameters on CT was assessed in relation to therapy response.Results Based on the standard of reference, 36 patients (26.3 %) had residual lymphoma. For IHP and Deauville criteria, sensitivity, specificity and accuracy were 97.2 %, 97.2 % (p= 1); 79.2 %, 92.1 % (p< 0.001); and 83.9 %, 93.4 % (p=0.001), respectively. Of the morphological parameters assessed, only change in size over course of therapy was significant (p<0.003) and improved specificity for IHP-based interpretation to 90.4 % (p=0.008). Conclusions Using liver as the visual reference to determine PET positivity for lymphoma patients being assessed for residual masses at the end of therapy improves specificity, yet maintains the high sensitivity of PET in identifying residual disease. The addition of change in size after therapy improves specificity of PET when using IHP-based but not Deauvillebased interpretation.

show abstract

Section: Discussionsupporting

confidence: 89%

FDG PET/CT Response Assessment Criteria for Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma at End of Therapy: A Multiparametric Approach

Metser

Mohan

Beckley

et al. 2015

Nucl Med Mol Imaging

View full text Add to dashboard Cite

show abstract

“…3 In addition, data regarding the reproducibility of interim PET interpretation have been published by Horning et al, 35 who concluded that there is still moderate examination reproducibility among nuclear medicine experts, thus indicating the need to standardize PET interpretation criteria in current clinical practice. A successful attempt has been documented by Barrington et al 36 for Hodgkin disease, wherein very good agreement was achieved in the reporting of interim PET scans between expert readers from 4 different European centers using a 5-point scale.…”

Section: Discussionmentioning

confidence: 98%

Midtreatment ¹⁸F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

Zinzani

Gandolfi

Broccoli

et al. 2010

Cancer

View full text Add to dashboard Cite

Herein, we report on direct preparation of macroporous polyimide (PI) films with pores distributing on one side, the method of which relies on sedimentation of ceramic spheres in polyamic acid (PAA) solutions in a gravitational field and imidization of PAA/ceramic spheres mixtures to obtain PI/ceramic spheres hybrid films followed by curing in dilute hydrofluoric (HF) acid. In this strategy, the curing of the hybrid films in HF acid leads to the formation of pores. The introduction of pores makes the room‐temperature dielectric constants of the macroporous films lower than that of pure PI film. Moreover, the macroporous PI films have improved Young's moduli and higher thermal stability in nitrogen atmosphere. © 2007 Wiley Periodicals, Inc. J Appl Polym Sci 104: 261–266, 2007

show abstract

“…A similar network established in the United Kingdom for clinical trials in classic Hodgkin lymphoma has found good concordance in PET in-terpretation in patients with advanced-stage classic Hodgkin lymphoma treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). 66 Although it may not be possible for every PET scan to be reviewed by a central panel of experts, these findings suggest that scans should be reported by experienced readers and equivocal scans possibly shared with other expert readers. Furthermore, the previous PET scans should always be accessed for comparison.…”

Section: Controversies In the Use Of Pet Scansmentioning

confidence: 99%

Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy

Ansell

Armitage

2012

Mayo Clinic Proceedings

View full text Add to dashboard Cite

The use of sensitive and specific imaging techniques for accurate initial staging and evaluation of response to therapy in patients with lymphoma is essential for their optimal management. Fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) integrated with computed tomography (CT) has emerged as a powerful imaging tool and is being routinely used in staging, response evaluation, and posttreatment surveillance in patients with non-Hodgkin lymphoma and Hodgkin lymphoma. PET/CT is currently widely used in clinical practice, but the established clinical benefit is currently restricted to the posttreatment evaluation of Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. Although used in other histologic subtypes and in other clinical situations including response assessment, its impact on patient outcome remains to be demonstrated. We performed a literature search of PubMed from 1999 to 2011 using the following keywords: PET scan, FDG-PET, PET/CT, lymphoma. This review addresses the challenges and controversies in the use of PET/CT scans in the management of patients with lymphoma. I n most patients with lymphoma, positron emission tomographic (PET) scans show abnormalities at diagnosis. Normal findings on the scan after therapy is highly predictive of a good prognosis, particularly in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and Hodgkin lymphoma. However, the optimal application of PET scans to the management of all patients with lymphoma remains problematic. The major controversies include the optimal timing of PET scans (for staging, during therapy, after completion of therapy, surveillance in remission), standardization of PET scan interpretation (visual interpretation compared with standard uptake value [SUV] calculation), what constitutes a positive PET scan result, and whether PET scans should be used to direct management (eg, does changing therapy in patients with positive findings on PET change outcome, should biopsies of sites with positive PET results be done routinely before a management change). Although a large body of literature addressing these topics exists, the studies are often difficult to compare, making definitive conclusions on all these issues difficult. The previously published studies often used different designs and variable reporting, making interpretation and comparison of the results difficult. In the early studies particularly, heterogeneous populations with different stages of disease and different histologic subtypes were included, making the clinical applicability of the studies' results difficult. More recent studies focusing on efforts to standardize the conduct and interpretation of PET scans and on riskadapted therapies based on interim PET scan results will, it is hoped, improve the management and outcome of patients with lymphoma. A literature search of PubMed from 1999 to 2011 was performed using the following keywords: PET scan, FDG-PET, PET/CT, lymphoma. We highlight the current standard use ...

show abstract

Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma

Abstract: The criteria developed for reporting in the RATHL trial are sufficiently robust to be used in a multicentre setting.

Cited by 295 publications

References 24 publications

FDG PET/CT Response Assessment Criteria for Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma at End of Therapy: A Multiparametric Approach

FDG PET/CT Response Assessment Criteria for Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma at End of Therapy: A Multiparametric Approach

Midtreatment ¹⁸F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy

Contact Info

Product

Resources

About

Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma

Abstract: The criteria developed for reporting in the RATHL trial are sufficiently robust to be used in a multicentre setting.

Cited by 295 publications

References 24 publications

FDG PET/CT Response Assessment Criteria for Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma at End of Therapy: A Multiparametric Approach

FDG PET/CT Response Assessment Criteria for Patients with Hodgkin’s and Non-Hodgkin’s Lymphoma at End of Therapy: A Multiparametric Approach

Midtreatment 18F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma

Positron Emission Tomographic Scans in Lymphoma: Convention and Controversy

Contact Info

Product

Resources

About

Midtreatment ¹⁸F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma